Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/15/2025

Anemia Management in Chronic Kidney Disease

Introduction to Anemia Management

  • Anemia is defined as a hemoglobin level less than 13 g/dL in men, less than 12 g/dL in non-pregnant women, and less than 11 g/dL in pregnant women, with specific values for children based on age group, according to the World Health Organization (WHO) 1
  • The diagnostic criteria for anemia include hemoglobin levels, with specific thresholds for different populations, such as men, non-pregnant women, pregnant women, and children of different age groups 1

Causes and Classification of Anemia

  • Anemia can be classified into different types based on the mean corpuscular volume (MCV), including microcytic, normocytic, and macrocytic anemia 2
  • The main causes of anemia include iron deficiency, thalassemia, anemia of chronic disease, and sideroblastic anemia 2, 3
  • Other causes of anemia include hemorrhage, hemolysis, bone marrow failure, and anemia of inflammatory disease 2
  • The following table summarizes key laboratory tests for anemia evaluation:
Test Description
Hemoglobin Measures the amount of hemoglobin in the blood
Reticulocyte count Evaluates bone marrow response to anemia
Iron studies Includes serum ferritin and transferrin saturation to assess tissue iron stores and iron available for erythropoiesis

Epoetin Therapy in Dialysis Patients

  • The most common cause of inadequate response to Epoetin in dialysis patients is iron deficiency, followed by infection/inflammation, chronic blood loss, and osteitis fibrosa, according to the American Journal of Kidney Diseases guidelines 4
  • Iron deficiency markedly impairs responsiveness to Epoetin, and inflammatory cytokines (tumor necrosis factor, interleukin-1) inhibit erythropoiesis in dialysis patients 4
  • Elevated C-reactive protein levels predict resistance to Epoetin in dialysis patients 4
  • Initial dosing of Epoetin alfa is 50-100 IU/kg three times weekly or 450 IU/kg once weekly subcutaneously, according to the American Journal of Kidney Diseases 4

Evaluation and Management of Hyporesponsiveness to Epoetin

  • If iron-replete, check for infection/inflammation by evaluating complete blood count, C-reactive protein, and access infections, peritonitis, or other inflammatory conditions 4
  • If no infection/inflammation, evaluate for chronic blood loss, including occult gastrointestinal bleeding, blood loss during dialysis, and other sources of bleeding 4
  • If no blood loss, check parathyroid hormone levels for secondary hyperparathyroidism 4
  • During intercurrent illness, continue Epoetin at a dose at least equal to pre-illness dose to allow for more prompt resumption of erythropoiesis once illness resolves 4
  • Continuing ineffective ESA therapy for more than 6-8 weeks (hemoglobin increase <1 g/dL) without reevaluating and adjusting treatment is not recommended, according to the American Journal of Kidney Diseases 4

Iron Supplementation and Monitoring

  • If iron deficient, initiate iron supplementation before or concurrent with ESA therapy, as recommended by the American Society of Nephrology 5
  • Iron supplementation should be started if iron deficient, with oral iron as first-line therapy at a dosing of 100-200 mg elemental iron daily in divided doses 4
  • Iron status should be assessed through serum ferritin and transferrin saturation (TSAT) checks, with target ferritin levels >100 ng/mL and TSAT >20%, according to guidelines from kidney disease experts 4
  • The following table summarizes the recommended monitoring schedule for patients with anemia:
Parameter Frequency
Hemoglobin every 2-4 weeks initially, then monthly once stable
Iron status every 3 months during treatment
Renal function regularly, with adjustment of anemia management as needed
Blood pressure with each dose of erythropoietin

Lifestyle Modifications and Nephrology Referral

  • Patients with CKD should adhere to a low sodium diet (2-3 g/day), moderate protein restriction (0.8 g/kg/day), engage in regular physical activity as tolerated, and manage their weight, as these lifestyle modifications support overall renal and cardiovascular health, as recommended by the National Kidney Foundation 6
  • Ensure adequate selenium intake (50-100 μg/day) and check vitamin D status, as recommended by the National Institutes of Health 7
  • Blood pressure should be controlled with a target <130/80 mmHg, considering ACE inhibitors or ARBs as first-line agents if not contraindicated, as per general hypertension management guidelines 8
  • Nephrology referral is indicated for Stage 3a CKD with anemia and electrolyte abnormalities, as suggested by kidney disease guidelines 9, 10